ANTI-Δ42PD1
ANTIBODY PLATFORM

PIPELINE
OUR
TEAM

Dr. Percy CHENG
MH
(Co-Founder)
Executive Director
Chairman of the Board

Dr. Xia JIN
(Co-Founder)
Executive Director
Chief Executive Officer

Mr. Peter TANG
(Co-Founder)
Director

Mr. Chibo TANG
Director

Dr. Che Hung LEONG, Edward
GBM, GBS, OBE, JP
Chairman of Advisory Board

Dr. Wing Man KO
GBS, JP
Advisory Board Member

Dr. Da I HO, David
Advisory Board Member

Prof. Zhiwei CHEN
(Co-Founder)
Advisory Board Member
and Principal Scientific Advisor

Mr. Tom LAU
(Co-Founder)
Director of Corporate Finance

Mr. Mark Lo
Chief Financial Officer

Dr. Michael WONG
Research and Development Director

Dr. Pele CHONG
Strategic Development Director

Dr. Sing Fai WAI
Chief Technology Officer

Ms. Ting WANG
Clinical and Regulatory Director

Mr. David Yanhua DU
General Manager of
Shenzhen Immuno Cure

Mr. Andy WONG
(Co-Founder)
Consultant

ABOUT
IMMUNO CURE
Immuno Cure is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody Immune Blocking technology platforms; with 2 vaccines in first-in-human clinical trials.
Learn More